A FURIOUS father has blasted retail bosses after being forced to carry his disabled daughter down an escalator in her ...

Learn what you need to do to have a fun, safe, and stress-free day at an amusement park when you have spinal muscular atrophy.

CINCINNATI (WKRC) - The annual "Cure SMA Walk-n-Roll" event kicked off Saturday morning at Xavier University, drawing participants to raise awareness and support for those living with spinal ...

Nearly six years ago, the Food and Drug Administration approved Zolgensma, a Novartis gene therapy for the fatal neuron-wasting disease spinal muscular atrophy. It heralded a new era of genetic ...

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before birth. Scientists at St. Jude Children's Research Hospital led the first in utero treatment of SMA ...

The disease Mitchell was diagnosed with, back in April 2017, was spinal muscular atrophy (SMA)—a rare, genetic neuromuscular disease that can affect individuals of any age.

Prenatal therapy for spinal muscular atrophy (SMA) with risdiplam has shown promise in a first-of-its-kind study led by Richard Finkel, MD, St. Jude Center for Experimental Neurotherapeutics ...

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA) – Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over ...

The pilot trial in three adults with SMA showed that epidural spinal cord stimulation (SCS), which involves electrical stimulation of the sensory spinal nerves, can gradually reawaken functionally ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease. An intervention ...

Spinraza, also known as nusinersen, is a medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families.

At the end of the 12-month trial, 25 of the 26 infants (96%) treated with Evrysdi were able to sit without support for at least five seconds. Also, 21 of the 26 infants (about 81%) were able to ...